These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9569119)

  • 1. Subcutaneous r-HuEPO therapy in CAPD patients: dose determination and clinical experience.
    Janicka L; Ksiazek A; Baranowicz I; Bednarek-Skublewska A; Mierzicki P; Ksiazek P
    Int Urol Nephrol; 1998; 30(1):91-7. PubMed ID: 9569119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy.
    Malik IA; Khan ZK; Hakimali A; Sabih M; Rehman G
    J Pak Med Assoc; 1998 May; 48(5):127-31. PubMed ID: 9813972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial.
    Sweeney PJ; Nicolae D; Ignacio L; Chen L; Roach M; Wara W; Marcus KC; Vijayakumar S
    Br J Cancer; 1998 Jun; 77(11):1996-2002. PubMed ID: 9667681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of subcutaneous recombinant human erythropoietin (r-Hu EPO) in CAPD patients with renal anaemia.
    Janicka L; Ksiazek A; Baranowicz I; Mierzicki P
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():67-77. PubMed ID: 8192534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response.
    Rutherford CJ; Schneider TJ; Dempsey H; Kirn DH; Brugnara C; Goldberg MA
    Am J Med; 1994 Feb; 96(2):139-45. PubMed ID: 8109598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of subcutaneous r-HuEPO in cancer patients receiving chemotherapy with anemia: a preliminary report.
    Chiou TJ; Chim YS; Wei CH; Hsieh RK; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Nov; 60(5):229-35. PubMed ID: 9509677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment.
    Hughes RT; Cotes PM; Pippard MJ; Stevens JM; Oliver DO; Winearls CG; Royston JP
    Br J Haematol; 1990 Jun; 75(2):268-73. PubMed ID: 2372513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.
    Shannon KM; Keith JF; Mentzer WC; Ehrenkranz RA; Brown MS; Widness JA; Gleason CA; Bifano EM; Millard DD; Davis CB
    Pediatrics; 1995 Jan; 95(1):1-8. PubMed ID: 7770284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
    Marques da Costa R
    Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter study with once a week or once every two weeks high-dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis.
    Nomoto Y; Kawaguchi Y; Kubota M; Tagawa H; Kubo K; Ogura Y; Shoji T; Kawada Y; Koshikawa S; Mimura N
    Perit Dial Int; 1994; 14(1):56-60. PubMed ID: 8312416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.
    Ludwig H; Sundal E; Pecherstorfer M; Leitgeb C; Bauernhofer T; Beinhauer A; Samonigg H; Kappeler AW; Fritz E
    Cancer; 1995 Dec; 76(11):2319-29. PubMed ID: 8635038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Numerical and functional alterations in T and B lymphocyte subpopulations in CAPD patients treated with recombinant human erythropoietin].
    Tanabe R
    Nihon Jinzo Gakkai Shi; 1994 Oct; 36(10):1159-68. PubMed ID: 7815748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of subcutaneous erythropoietin in CAPD patients.
    Piraino B; Johnston JR
    Clin Nephrol; 1990 Apr; 33(4):200-2. PubMed ID: 2350907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of anemia in patients with renal failure using erythropoietin obtained by genetic recombination].
    Wiecek A; Kokot F; Grzeszczak W; Klin M
    Pol Tyg Lek; 1990 Sep 17-24; 45(38-39):782-6. PubMed ID: 2095546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel.
    Yagil Y
    Isr J Med Sci; 1997 Jan; 33(1):36-44. PubMed ID: 9203516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial.
    Vijayakumar S; Roach M; Wara W; Chan SK; Ewing C; Rubin S; Sutton H; Halpern H; Awan A; Houghton A
    Int J Radiat Oncol Biol Phys; 1993 Jul; 26(4):721-9. PubMed ID: 8331011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous.
    Hörl WH
    Acta Haematol; 1992; 87 Suppl 1():16-9. PubMed ID: 1574961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of human recombinant erythropoietin on anaemia and dialysis efficiency in patients undergoing continuous ambulatory peritoneal dialysis.
    Steinhauer HB; Lubrich-Birkner I; Dreyling KW; Schollmeyer P
    Eur J Clin Invest; 1991 Feb; 21(1):47-52. PubMed ID: 1907554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.